Covid-19: From the analysts

10 April 2020 (Last Updated April 10th, 2020 10:36)

NHS assesses risk of Covid-19 infection in rheumatology patients
Many patient groups are at an increased risk of infection due to the global Covid-19 pandemic, extending to rheumatology patients who have been prescribed immunosuppressant medication. Although rheumatology patients are not the most at-risk demographic, the coronavirus outbreak has presented these patients with medical and logistical difficulties that can jeopardise their treatment.

Covid-19 cases may have peaked in Italy while US and UK will see the worst yet
Italy appears to have reached a plateau in the number of new cases of Covid-19 in the past week, but the US and the UK have yet to reach the peak. Nonetheless, none of the countries are near to being done with the pandemic. GlobalData estimates that it will take an additional one- to two-month time of continued strict social distancing efforts post peak before new cases will decrease to near zero.

The use of biomarkers to propel Covid-19 trials
With the number of Covid-19 trials steadily increasing, most are including biomarkers to help speed up the trials and reduce the cost of drug development. Even with standard trials, biomarkers can help reduce trial times, verify a drug’s mechanism of action, guide subject and dose selection, and minimise patient safety risks.